Reference : Long-term follow-up reveals low toxicity of radiosurgery for vestibular schwannoma
Scientific journals : Article
Human health sciences : Oncology
Human health sciences : Surgery
Human health sciences : Radiology, nuclear medicine & imaging
http://hdl.handle.net/2268/39967
Long-term follow-up reveals low toxicity of radiosurgery for vestibular schwannoma
English
Rutten, Isabelle [> > > >]
Baumert, B. G. [> > > >]
Seidel, Laurence mailto [Université de Liège - ULg > Département des sciences de la santé publique > Informatique médicale et biostatistique >]
Kotolenko, S. [> > > >]
Collignon, Jacques mailto [Centre Hospitalier Universitaire de Liège - CHU > > Imagerie médicale >]
Kaschten, Bruno mailto [Centre Hospitalier Universitaire de Liège - CHU > > Neurochirurgie >]
Albert, Adelin mailto [Université de Liège - ULg > Département des sciences de la santé publique > Informatique médicale et biostatistique >]
Martin, Didier mailto [Université de Liège - ULg > Département des sciences cliniques > Neurochirurgie]
Deneufbourg, Jean-Marie mailto [Université de Liège - ULg > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine) >]
Demanez, Jean-Pierre mailto [Université de Liège - ULg > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine) >]
Stevenaert, Achille mailto [Université de Liège - ULg > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine) >]
Jan-2007
Radiotherapy & Oncology
Elsevier Ireland Ltd
82
1
83-89
Yes (verified by ORBi)
International
0167-8140
Clare
[en] radiosurgery ; vestibular schwannomas ; cranial nerve toxicity
[en] AIM: The long-term effects of radiosurgery of vestibular schwannomas were investigated in a group of consecutively treated patients. METHODS AND MATERIALS: Between 1995 and 2001, 26 patients (median age: 67, range: 30-82) with a vestibular schwannoma were treated by Linac-based stereotactic radiosurgery (SRS). The median follow-up was 49 months (16-85 months). Only progressive tumours were treated. The median size of tumours was 18 mm (range 9-30 mm). Before SRS, 11 patients had a useful hearing (Gardner-Robertson classes 1 and 2). Single doses of 10-14 Gy were prescribed at the 80% isodose at the tumour margin. The follow-up consisted of regular imaging with MRI the first 3-6 months after the intervention, followed by additional yearly MRIs, a hearing test and a neurological examination. RESULT: The 5-year-probability of tumour control (defined as stabilization or decrease in size) was 95%. Five-year-probability of preservation of hearing and facial nerve function was 96% and 100%, respectively. Hearing was preserved in 10 out of 11 patients who had a normal or useful hearing at the time of treatment. Mild and transient trigeminal toxicity occurred in 2 (8%) patients. It appeared to be significantly correlated to the dose used (p=0.044). However, only a tendency to significance could be demonstrated in the relationship between the two factors when using the Cox analysis (hazard ratio=1.7; 95% CI: 0.7-3.9; p=0.23). CONCLUSIONS: With the doses used, our study demonstrates that SRS provides an equivalent tumour control rate when compared to surgery, as well as on a long-term basis, an excellent preservation of the facial and the acoustic nerves. Although no permanent trigeminal toxicity was observed, our data confirm that doses below 14 Gy can avoid transient dysesthesias.
http://hdl.handle.net/2268/39967
10.1016/j.radonc.2006.11.019

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
20100511132113179.pdfPublisher postprint1.15 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.